home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410b.zip
/
M94A0278.TXT
< prev
next >
Wrap
Text File
|
1994-10-08
|
2KB
|
28 lines
Document 0278
DOCN M94A0278
TI Controversial aspects in the management of vulvovaginal candidiasis.
DT 9412
AU Sobel JD; Division of Infectious Disease, Wayne State University School
of; Medicine, Detroit, MI.
SO J Am Acad Dermatol. 1994 Sep;31(3 Pt 2):S10-3. Unique Identifier :
AIDSLINE MED/94358234
AB Numerous highly effective topical vaginal antimycotic agents are
available that provide high cure rates with a favorable therapeutic side
effect ratio. Recently three oral systemic azole agents have been added.
Therapeutic options afford the opportunity of customizing therapy to
achieve optimal cure rates. At the same time, several new complex issues
have appeared that constitute new challenges to successful management,
such as women with human immunodeficiency virus infection and infection
caused by non-albicans Candida species and resistant strains of Candida
albicans.
DE Acquired Immunodeficiency Syndrome/COMPLICATIONS Acute Disease
Administration, Oral Administration, Topical Antifungal
Agents/*THERAPEUTIC USE Candidiasis, Vulvovaginal/COMPLICATIONS/*DRUG
THERAPY/IMMUNOLOGY Dose-Response Relationship, Drug Drug Resistance,
Microbial Female Human Male Recurrence JOURNAL ARTICLE REVIEW
REVIEW, TUTORIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).